These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4153252)

  • 21. [Analysis of a therapeutic failure of L-Dopa: can Adams-Van Bosaert and Van Der Eecken's strio-nigral degeneration be diagnosed during the patient's life?].
    André JM; Royer RJ; Duc M; Kissel P
    Rev Neurol (Paris); 1974; 130(7-8):322-6. PubMed ID: 4453761
    [No Abstract]   [Full Text] [Related]  

  • 22. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 23. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease.
    Hauser RA; Olanow CW
    Mov Disord; 1993 Oct; 8(4):512-4. PubMed ID: 8232363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease.
    Morley JB
    Aust Fam Physician; 1977 Jan; 6(1):29-30, 32, 34-5. PubMed ID: 16582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology of Parkinson's disease.
    Burton K; Calne DB
    Neurol Clin; 1984 Aug; 2(3):461-72. PubMed ID: 6152482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-Dopa therapy in Parkinson's disease.
    Greer M
    J Fla Med Assoc; 1970 Jun; 57(6):23-7. PubMed ID: 4392779
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pallido-nigral degeneration--a case of Parkinson's syndrome resistant to L-dopa].
    Matsuoka Y; Muroga T; Wakayama Y; Sugimura K; Matsui T
    Rinsho Shinkeigaku; 1977 Jan; 17(1):46-51. PubMed ID: 557400
    [No Abstract]   [Full Text] [Related]  

  • 30. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 31. [Parkinsonism].
    Kaumeier S
    Fortschr Med; 1978 Jul; 96(28):1397-404. PubMed ID: 27434
    [No Abstract]   [Full Text] [Related]  

  • 32. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 33. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
    Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
    Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [L-dopa + peripheral decarboxylase antagonist].
    Wiesel FA
    Lakartidningen; 1975 Oct; 72(43):4173. PubMed ID: 1177632
    [No Abstract]   [Full Text] [Related]  

  • 35. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 36. [Progress in therapy of Parkinsonian syndrome].
    Völler GW
    Hippokrates; 1975 Feb; 46(1):17-33. PubMed ID: 1091605
    [No Abstract]   [Full Text] [Related]  

  • 37. [Neurological aspects and modern trends in therapy of Parkinson's disease].
    Pavoncello S; Di Bianco V; Di Castro A; Caviglia A; Cellitti M
    Clin Ter; 1980 Feb; 92(4):433-8. PubMed ID: 7449321
    [No Abstract]   [Full Text] [Related]  

  • 38. [Neurochemical aspects of Parkinson tremor].
    Agostini L; Firenze C; Gallai V; Piccinin GL; Piccirilli M; Rossi A
    Clin Ter; 1979 Apr; 89(2):119-25. PubMed ID: 487712
    [No Abstract]   [Full Text] [Related]  

  • 39. [L-dopa-resistant Parkinson's disease with cerebral atrophy: striato-nigral degeneration?].
    Dell'Aria V; Ciannella L; Melone MA
    Acta Neurol Quad (Napoli); 1981; 42():212-5. PubMed ID: 7270052
    [No Abstract]   [Full Text] [Related]  

  • 40. [L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
    Lakke JP; Nienhuis RJ; Meyer R; Zwols F; Schut T
    Ned Tijdschr Geneeskd; 1972 Nov; 116(48):2180-4. PubMed ID: 4639072
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.